EYLIO

What EYLIO does

EYLIO (EYLIO SAS) is a French pharmaceutical services company founded in 2019 by Jérémy Amzallag and headquartered at the Illkirch-Graffenstaden biopole in Grand Est, France. The company provides external Qualified Person (QP) services to biotechnology and pharmaceutical companies, including QP Batch Certification, QP Batch Confirmation, and QP Declarations for both marketing-authorized products and investigational medicinal products (IMPs), operating under dual authorization from ANSM (human drugs) and ANSES (veterinary drugs) and in compliance with EU GMP Annex 16.

Its service portfolio spans the full drug development lifecycle: QP release services, regulatory expertise and development strategy, manufacturer audits with CAPA follow-up, external quality assurance systems (SOPs, change control, training), project management for clinical trials (kit design, CMO selection, packaging oversight), temperature-controlled storage from -80°C to 25°C across 150m²+ of operational area, quality control identification, and — following 2024 commissioning — a 200m² GMP-compliant production and packaging area for pre-clinical through Phase II drugs. Revenue is generated through professional services engagements (per-batch certification fees, audit and regulatory consulting, project-based clinical trial management) and usage-based storage fees, priced custom per engagement under multi-year contracts with biotech, pharmaceutical laboratories, and veterinary pharma clients; the company reports 50+ clients internationally and a team of 10 Expert and Qualified Persons.

Go-to-market is enterprise field sales: direct B2B engagement with pharmaceutical and biotech companies, supported by the company website, LinkedIn presence, and personalized consultation, with international scope anchored in EU GMP expertise. The company is privately held and founder-controlled, with no disclosed funding rounds, parent company, or institutional investors.

Name

EYLIO

Legal name

EYLIO SAS

Website

https://eyliopharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

EYLIO is a French pharmaceutical services firm, authorized by ANSM and ANSES, providing external Qualified Person batch certification, regulatory expertise, audits, clinical trial project management, and temperature-controlled storage for biotech and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Pharmaceutical QP services
• Qualified person certification
• GMP compliance auditing
• Clinical trial project management
• Biotech drug development

Headquarters

HQ city

Illkirch-Graffenstaden

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Qualified Person Services: QP batch certification, QP declaration, and QP batch confirmation services for pharmaceutical products. Revenue generated through per-batch certification fees and service contracts for clinical and commercial products.
2. Quality Services: Quality audits of manufacturers, regulatory expertise, product specification files, and external quality assurance system management. Recurring and project-based consulting engagements.
3. Project Management Services: Clinical trial project management including kits design, CMO selection, manufacturing oversight, and distribution coordination. Typically project-based engagements.
4. Storage Services: Temperature-controlled storage from -80°C to 25°C for IMP, DS, and DP products. Revenue based on storage volume and duration.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

EYLIO provides Qualified Person (QP) services and pharmaceutical support to biotech and pharmaceutical companies, including QP batch certification, QP declaration, and QP batch confirmation for clinical trials and EU marketing authorization. Its portfolio extends to quality audits, regulatory expertise, external quality assurance systems, clinical trial project management, temperature-controlled storage (-80°C to 25°C), quality control, and small-batch manufacturing, packaging, and distribution. The company is authorized by ANSM and ANSES to act as a pharmaceutical establishment.

Product overview

EYLIO is a pharmaceutical services company offering a unified platform of Qualified Person (QP) services for biotech companies. The portfolio centers on QP Batch Certification, QP Batch Confirmation, and QP Declaration services, complemented by Quality Services (audits, regulatory expertise, external quality assurance) and Project Management for clinical trials. The company also provides operational infrastructure including GMP-compliant storage (from -80C to 25C), quality control, and manufacturing/packaging/distribution capabilities, aiming to be a complete turnkey partner from pre-clinical phase through Phase II drug development.

Differentiator

Problem solved

Functional benefit

Products and services

• QP Batch Certification Release of finished products for use in the EU for marketing authorization or for clinical trials, in conformity with Annex 16 of GMP guidelines. Targeted at biotech companies and pharmaceutical laboratories requiring QP certification for drug batches.
• QP Batch Confirmation Signed statement confirming that a manufacturing step (such as bottling of tablets) has been conducted in accordance with EU GMP and PSF or CTD standards. Targeted at pharmaceutical manufacturers requiring certification of intermediate manufacturing steps.
• QP Declaration Declaration safeguarding that Investigational Medicinal Product (active or placebo substance) or Marketed Product has been manufactured in accordance with EU GMP standards, covering assumption of responsibility for raw materials manufactured in third countries. For pharmaceutical companies importing products into the EU.
• Importation Services Request for import authorization from French authorities, enabling international drug product movement and regulatory compliance. For pharmaceutical companies needing to import products into the EU.
• Quality Audits and CAPAs Follow-up Audits of manufacturers of Drug Substances and Drug Products, Packagers, Warehouses, and Quality Control Laboratories related to GMP compliance for Investigational Medicinal Product or Marketed Product, including CAPA follow-up. For biotech and pharmaceutical companies requiring GMP compliance oversight.
• Regulatory Expertise Advice on GMP compliance, Development Plan and Strategy Definition, accompanying biotechnology laboratories on the regulatory level. For biotech companies navigating pharmaceutical regulatory requirements.
• Product Specification Files Reference file with all information necessary to draft detailed written instructions on processing, packaging, quality control testing, and batch release. For pharmaceutical companies developing or manufacturing drug products.
• External Quality Assurance System QMS plan definition, SOP writing, Change Control, Training documentation, CAPAs management, Follow-up of subcontractors (Quality Contracts, Deviations, Audits), and Follow-up of quality indicators. For biotech companies lacking internal QMS infrastructure.
• Project Management in Clinical Trials Support in DS/DP manufacturing steps and packaging steps including writing contracts (QTA, Specifications), operations follow-up, kits design and needs definition, CMO selection, management and follow-up, GANTT charts establishment, and monitoring shipments. For clinical trial sponsors and biotech companies.
• Storage Services IMP Storage from -80°C to 25°C in a secure area; DS/DP Storage (bulks) from -80°C to 25°C in a secure area. Operational storage area of more than 150m². For biotech and pharmaceutical companies requiring temperature-controlled storage of pharmaceutical products.
• Quality Control Services QC Identification services for drug products in development. For biotech and pharmaceutical companies requiring analytical quality control support.
• Manufacturing, Packaging, and Distribution Services Fill & Finish: Small Batch Production of active/placebo products; Secondary packaging, clinical labelling and blinding; Distribution to Investigational Sites; Return & Destruction services. For biotech companies and clinical trial sponsors needing small-batch manufacturing and clinical packaging.

Quantifiable outcome

• 50+ clients served internationally
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Fareva: French pharmaceutical group with manufacturing, packaging, and development services across multiple dosage forms. Comparable to EYLIO as a French-rooted pharma services provider serving EU clients with GMP-related offerings, though Fareva operates at substantially larger scale.
• ICON plc: Global CRO providing clinical research, bioanalytical, and consulting services to pharma and biotech. Comparable to EYLIO on clinical trial project management and biotech-facing services but operates at vastly larger scale with a much broader service portfolio.
• Delpharm: French-headquartered CDMO with multiple manufacturing sites offering contract manufacturing and QP-related services for European pharma and biotech. Comparable to EYLIO in its French roots and EU-centric regulatory capabilities but at significantly larger scale.
• Recipharm: European CDMO offering pharmaceutical development, manufacturing, and QP services across multiple dosage forms. Directly comparable to EYLIO on EU QP release and GMP services but with broader scale, multiple sites, and a wider service portfolio.
• Eurofins: Global leader in bioanalytical, pharmaceutical, and clinical testing services with a broad portfolio that includes regulatory/QA consulting (via acquired entities such as PharmaLex). Comparable to EYLIO on QA, regulatory, and pharmaceutical testing services but at vastly greater scale.
• Lonza: One of the world's largest CDMOs with comprehensive small-molecule, biologic, and cell-and-gene therapy capabilities including QP release for clinical and commercial supply. Overlaps with EYLIO on QP release and EU GMP-related activities but serves a global, diversified customer base.
• Catalent: Global CDMO offering development, manufacturing, and QP release services across oral, biologic, and cell therapy modalities. Comparable to EYLIO as a QP/regulatory services provider but at vastly greater scale and as part of a much broader CDMO portfolio.
• Aenova: European CDMO offering development and manufacturing of solid, semi-solid, liquid, and sterile dosage forms with QP-relevant services. Comparable to EYLIO on EU pharma services and QP-adjacent capabilities, though Aenova serves a much larger and more diversified client base.

Direct peers

• Pharmalex GmbH: Specialized regulatory affairs, pharmacovigilance, and quality/compliance consulting firm (now operating under Eurofins) that historically provided QP and regulatory consulting to pharma and biotech. Most directly comparable peer to EYLIO on regulatory/QP/QA services for biotech clients.
• Myonex (formerly VCLS): Clinical trial supply and QP services company that absorbed VCLS (Vaccine and Cell Logistics Services), a French provider of clinical supply chain, QP release, and storage services. Closely comparable to EYLIO on clinical trial supply, QP release, and temperature-controlled storage offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eylio-sas

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EYLIO